MMJ Files FDA Fast Track Approval Application For Cannabis Multiple Sclerosis Drug

FDA grants Fast Track Designation to help expedite the review and approval of drugs in development that treat serious or life threatening diseases and fill an unmet medical need. MMJ International Holdings will be one of the world’s first natural plant-derived cannabinoid prescription drugs once approved by the FDA for the treatment of spasticity and pain due to multiple sclerosis.

RESTON, Va. (PRWEB) February 13, 2019 -- MMJ International Holdings, the premier medical cannabis research company, is advancing the science of medical marijuana legally through patient clinical trials and research, announced that it is seeking fast track designation approval from the FDA.

The FDA grants Fast Track Designation to help expedite the review and approval of drugs in development that treat serious or life threatening diseases and fill patients unmet medical needs. MMJ-001 the companies new cannabis based pharmaceutical drug for multiple sclerosis will show robust treatment results.

The MMJ Group is focused on collaborative scientific research projects that follows the FDA guidelines. MMJ will conduct its clinical trials to fully explore the potential of cannabis medicine for progressive Multiple Sclerosis and Huntington's patients.

Bianca Weinstock-Guttman MD, MMJ International Holding’s principal investigator is a widely known leading expert on multiple sclerosis (MS) in adults and children. She also is a Professor of Neurology at the State University of New York at Buffalo who serves as Executive Director of the New York State Multiple Sclerosis Consortium. Dr. Weinstock-Guttman will oversee the FDA approved study exploring the potential therapeutic applications of cannabinoids for progressive multiple sclerosis patients.

MMJ International Holdings will begin a first "dose ranging" study comparing its pharmaceutical formulation of THC and CBD to placebo. It is expected that the study will demonstrate acceptable tolerable patient doses of the medicine.

Duane Boise the company’s CEO stated, "The positive data from this dosing study is important in that it will provide us with the necessary evidence on patient tolerance to different doses of THC and CBD for the treatment for PPMS. This information will prove value to assist clinicians with prescribing decisions to address individual patient needs should this medicine be FDA approved for use."

MMJ International Holdings team continues to evaluate numerous plant derived cannabinoid medicines and currently has several planned clinical trials including Huntington’s disease. MMJ International Holdings will be one of the world’s first natural plant-derived cannabinoid prescription drugs once approved by the FDA for the treatment of spasticity and pain due to multiple sclerosis. For further information, please visit www.mmjih.com
Contact Information
Michael Sharpe
MMJ International Holdings
http://www.mmjih.com
800-586-7863

Online Web 2.0 Version
You can read the online version of this press release here.